The marginally enhanced tumor control observed with this single modification may be attributed to the large increase in the number of PRDM1 KO CAR T-cells in vivo, despite upregulation of exhaustion pathways and concomitantly diminished effector function. Here, PRDM1 is linked to neoplasm.